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Abstract: Under CuBr·SMe2/PPh3 catalysis (5/10 mol-%) RMgCl (R = Me, Et, nPr, CH=CH2, 
nBu, iBu, nC5H11, cC6H11, Bn, CH2Bn, nC11H23) readily (-78 oC) undergo 1,4-addition to Cbz or 
Boc protected quinolin-4(1H)-ones to provide 2-alkyl-2,3-dihydroquinolin-4(1H)-ones (14 
examples, 54-99% yield). Asymmetric versions require AlEt3 to Boc-protected ethyl 6-
substituted 4(1H)-quinolone-3-carboxylates (6-R group = all halogens, n/i/t-alkyls, CF3) and 
provide 61-91% yield, 30-86% ee; any halogen, Me, or CF3 provide the highest 
stereoselectivities (76-86% ee). Additions of AlMe3 or Al(nC8H17)3 provide ~45 and ~75% ee 
on addition to the parent (6-R = H). Ligand (S)-(BINOL)P-N(CHPh2)(cC6H11) provides the 
highest ee values engendering addition to the Si face of the 4(1H)-quinolone-3-carboxylate. 
Allylation and deprotection of a representative 1,4-addition product example confirm the facial 
selectivity (X-ray).  
 
Introduction 
Quinolone sub-structure cores 1a and their dihydro-analogues 1b (Scheme 1) constitute 
privileged starting materials in medicinal and natural product chemistry. The former core has 
been a lynchpin in antibiotic development for more than 50 years,[1] most recently in quorum 
sensing approaches, e.g. the moderation of bacterial activity engendered by species such as 
2.[2] The latter core 1b has been deployed in the syntheses of a range of natural and 
biologically active molecules, for example Ma’s intermediate (3)[3], used in the synthesis of 
martinellic acid (a natural Bradykinin antagonist); and in the related 4; active at 7 nM towards 
5-HT6 serotonin receptors.[4] Compounds 3-4 are exemplary of the recent move to explore sp3 
rich heterocycles in medicinal chemistry.[5] Such concepts are poorly explored for 
dihydroquinolones, with 5 being  the only common ‘model compound’ encountered, providing 
significant stereoselectivities for aryl additions and being attained by either Rh-[6] or Pd-
catalysed[7] ArM (M = ZnCl, BAr3),  addition providing 6c (R = aryl) in 40-99+% ee, or by a 
variety of organocatalytic closures (0-99+% ee) leading to the same core but from different 2-
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aminochalcone and related intermediates.[8] As both these approaches do not presently allow 
access to more biologically more interesting sp3 substituents (e.g. 3-4 etc.) we sought to 
study presently less explored alkyl organometallic additions to 6c. This seemed potentially 
profitable as catalytic enantioselective 1,4 alkyl additions to related 6a-b (Y = O, S with R = 
alkyl) are already known (9-96% ee).[9] 
 
Scheme 1. Quinolone and derived dihydro-analogues of relevance to this publication.  
 
Results and Discussion 
Additions to protected quinolin-4(1H)-ones (7)  
The protected acceptors 7a-d (within Table 1) are readily accessible from commercial quinolin-
4(1H)-one, which is itself also available from 2-nitroacetophenone via standard heterocylic 
chemistry.[10] As stoichiometric copper reagents had already been used in copper-promoted 
additions to 7a (for aza analogues of the natural product Wrightiadione.[11]), we tested this 
substrate under catalytic conditions, but it proved too deactivated to react. The more electron 
deficient 7b still performed poorly with ZnEt2 or AlEt3, under typical conjugate addition 
conditions. Runs 1-2 were the best outcomes we could attain from a range of conditions. As we 
could readily confirm that the stoichiometric cuprate MgBr[CuEt2] readily added to 7b in THF 
upon reaction at -78 to -20 oC affording a 65% isolated yield of 8b we trialled catalytic 
versions of this chemistry. In the absence of added ligands conversions were modest in THF 
(Run 3), and worse upon addition of Et2O (Run 4) due to the insolubility of 7b in this solvent. 
Remarkably, although 7b is also insoluble in 2-MeTHF at low temperature, this solvent 
produced a very rapid 1,4-addition (within 5 mins), which could be somewhat further 
promoted by simple phosphorus ligand addition (Runs 5-7). Simply increasing the overall 
reaction time to 1 h led to complete conversion in both the Cbz and Boc protected quinolin-
4(1H)-ones (7b-c) (Runs 8-9) while the methyl carbamate (7d) was inferior (Run 10). By 
employing these optimal conditions of Table 1 we could show the synthetic scope of the 2-
MeTHF reaction conditions (Scheme 2); which contains compounds of clear synthetic and 
biological utility. Species 8b-c and 9 have only been mentioned passingly in alternative 
methodology aimed at biologically active targets,[12] while all other isolated examples in 
Scheme 2 are novel. Certain limitations were noted in the chemistry of Scheme 2: (i) the 
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lowest yields were associated with addition of MeMgX to 7b while 7c did not participate in the 
same reaction; (ii) the catalytic reaction is sensitive to α-branching in the Grignard (e.g. 
iPrMgBr and PhMgBr do not react and cC6H11MgBr give a reduced yield; (iii) Allyl Grignard did 
not participate in the reaction.   
 
Table 1. Optimisation of EtMgBr addition to N-protected quinolin-4(1H)-ones 7. 
 
Run 7 MEt Cu-source Ligand Solvent Temp (oC) Time Conv. 
(%)[a] 
1 7b ZnEt2 Cu(OAc)2 P(OPh)3 THF -10 12 h − 
2 7b AlEt3 Cu(OTf)2 P(OPh)3 THF -10 18 h <25 
3 7b EtMgBr CuBr·SMe2 − THF -50 to -10 1.5 h 34 
4 7b EtMgBr CuBr·SMe2 − THF/Et2O (1:1) -78 to -20 1 h 31 
5 7b EtMgBr CuBr·SMe2 − 2-MeTHF -78 5 min 75 
6 7b EtMgBr CuBr·SMe2 P(OPh)3 2-MeTHF -78 5 min 88 
7 7b EtMgBr CuBr·SMe2 PPh3 2-MeTHF -78 5 min 96 
8 7b EtMgBr CuBr·SMe2 PPh3 2-MeTHF -78 1 h >99[b] 
9 7c EtMgBr CuBr·SMe2 PPh3 2-MeTHF -78 1 h >99[c] 
10 7d EtMgBr CuBr·SMe2 PPh3 2-MeTHF -78 1 h 78 
[a] Determined by 1H NMR on the crude reaction mixture. [b] Isolated yield 80%. [c] Isolated 
yield 99%. 
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Scheme 2. Scope and limitations of CuBr·SMe2/PPh3 catalysed 1,4 Grignard addition to 
acceptors 7. Isolated yields. 
Having established viable catalysis we turned our attention to the potential for an asymmetric 
version. Using the conditions of Scheme 2 but truncating the reaction time to just 2.5 minutes 
for the EtMgBr 1,4-addition to 7b is instructive. In the absence of any added ligand CuBr·SMe2 
(5 mol-%) a 35% conversion to 8b is already realised. In the presence the same copper 
loading and conditions, but with added phosphine ligands (10 mol-%) improved conversions 
are realised: P(OPh)3 (88%), PPh3 (73%) and P(cC6H11)3 (92%). This indicates that any ligand 
accelerated catalysis[13] is modest and not strongly affected by the σ/ϖ-donor characteristics of 
the phosphine. In line with these observations screening of a small diverse library of chiral 
ligands (exemplars LA-LF)[10] produced at best 1-11% ee at conversions of 21-76%.  The low 
levels of asymmetric induction realised are likely due to diverse substrate coordination shown 
by Mg(II) in 2-MeTHF.[14]  
 
Additions to Boc-protected ethyl 6-substituted 4(1H)-quinolone-3-carboxylates (26) 
One way to overcome the issues raised by substrates 7 is to add additional coordinative 
groups to the acceptor to provide both greater control of the asymmetric transition state 
conformation and increase its reactivity allowing the use of more selective (more covalent) 
organometallics (ZnR2, AlR3). Substrates 23[15]-24[16] (Scheme 3) represent examples of such 
approaches. We therefore initiated study of acceptors 26 which are attractive due to their 
similarity to Schmalz’s asymmetric synthesis of Vitamin E (94% ee for 1,4 AlMe3 addition);[17] 
and as Scammells has described very short preparation of the parent precursor 25a. 
 
Scheme 3. Preferred heterocyclic motifs for improved selectivity in asymmetric additions and 
the synthesis of preferred acceptor 26. 
Synthesis of the acceptor library 26a-k proceeded as expected,[10] but two points are worth 
noting: (i) the use of Eaton’s reagent to cyclise the 6-substituted 4-oxo-1,4-dihydroquinolines 
25 is much preferred over traditional phosphoric acids or high temperature cyclisations in Ph2O 
and we found this can be telescoped into a one-pot procedure; (ii) in Boc protection of 25, 
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washing with LiCl(aq) to remove DMF avoids the degradation that even mildly acidic washes 
would cause. 
Preliminary investigations focused of asymmetric catalytic studies on 26a (Table 2). Previous 
studies had already revealed the ethyl ester is preferred over both smaller and larger groups 
(Me, CHPh2) are inferior and that phosphoramidites are the optimal ligand class. The ligand 
structures used in the final optimisation are shown in Scheme 4. 
Table 2. Optimisation of AlEt3 addition to Boc-protected 4(1H)-quinolone-3-carboxylate 26a. 
 








1 AlEt3 Cu(OTf)2 LG CH2Cl2 -10 <0.1  >99 <1 
2 AlEt3 Cu(OTf)2 LG THF -10 0.5  >99 -18 
3 AlEt3 Cu(OTf)2 LG Et2O -10 1  >99 40 
4 AlEt3 Cu(OTf)2 LG Et2O -25 1  >99 60 
5 AlEt3 Cu(OAc)2 LG Et2O -25 3  96 52 
6 AlEt3 Cu(MeCN)4BF4 LG Et2O -25 3  98 45 
7 ZnEt2 Cu(OTf)2 LG Et2O -25 <0.1 >99 15 
8 AlEt3 Cu(OTf)2 LG Et2O -40 6  98-99 65 
9 AlEt3 Cu(OTf)2 LG Et2O -40 6-24  >99[b] 65 
10 AlEt3 Cu(OTf)2 LH Et2O -40 24  22 – 
11 AlEt3 Cu(OTf)2 LI Et2O -40 24  87 5 
12 AlEt3 Cu(OTf)2 LJ Et2O -40 24  >99 12 
13 AlEt3 Cu(OTf)2 LK Et2O -40 24  >99 26 
14 AlEt3 Cu(OTf)2 LL Et2O -40 24  >99 2 
15 AlEt3 Cu(OTf)2 LM Et2O -40 24  >99 70 
16 AlEt3 Cu(OTf)2 LN Et2O -40 24  >99[c] 77[d] 
 
[a] Determined by 1H NMR on the crude reaction mixture. [b] Isolated yield 68%. [c] Isolated 
yield 73%. [d] 77-82% ee at 4 mol-% Cu(OTf)2 and 8 mol-% LN. 
 
Scheme 4. Ligands used for catalytic asymmetric additions of MR to acceptor 26a.  
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Initial trials (Table 2) identified Et2O as an optimal solvent (Runs 1-3) and that copper(II) 
triflate was the optimal pre-catalyst for asymmetric AlEt3 1,4-addition (Runs 4-6) using (S,R,R) 
Feringa’s ligand LG as a starting phosphoramidite. Alternative additions of ZnEt2 provided 
poorer performance (Run 7 is representative). For AlEt3 additions cooling the reaction to -40 oC 
led to the highest ee value, but an increase in reaction time is required (Runs 8-9). We 
postulate that the success of the ether solvent is due to the relative insolubility of 26a in it at 
low temperature which somewhat moderates background (uncatalysed) reactions. At -40 oC in 
the absence of any catalyst a 74% conversion of 25a is seen at 24 h. Lower temperatures 
could not be used to further moderate this, as all reactions (catalysed or background) shut 
down at -50 oC. We have seen similar effects before.[16] Ligand modification to include addition 
coordination (LI, Run 11), increase in steric bulk of both the amine (LJ) or atropisomeric diol 
(LK) (Runs 12-13) had detrimental effects on the selectivity. The performance of the 
dissymmetric ligands (LL-LN) was maximised for a cyclohexyl substituent (Runs 14-16). 
Finally, as the reaction is close to viability at -40 oC we assured its reproducibility, performance 
and conversion by increasing the catalyst loadings to 4 mol-% Cu(OTf)2 and 8 mol-% LN. Using 
these optimised conditions we investigated the effect of the 6-substituent on the catalytic 
reaction performance (Scheme 5). 
 
Scheme 5. Scope and limitations of substitution patterns for 4(1H)-quinolone-3-carboxylate 
acceptors. 
The behaviour of 27a-k indicate that electron withdrawing groups in the 6-position increase 
the stereoselectivity of AlEt3 1,4-addition. Steric demand in the 6-position has a detrimental 
effect on the selective transition state, but less so than electron factors. With respect to the 
alane, AlMe3 reversed the sense of asymmetric induction (28), but longer linear alkyl chains 
were tolerated and behaved similarly to AlEt3 (29). Disubstituted 30-31 are clearly not 
accepted by the reaction transition state, but the root cause of this issue is not apparent at 
present. Due to the apparent reversals of enantioselectivity (e.g. 27a vs. 28), based on sign 
of optical rotation and HPLC enantiomer elution order, it became important to identify the 
absolute sense of the asymmetric induction engendered by (S)-LN in AlEt3 addition to 26a, and 
by implication other combinations of acceptors and alanes. Unfortunately, all of the direct 
conjugate addition products 27 we encountered were oils. However, we could overcome this 
issue and attain a crystalline derivative by manipulation of 27a (Scheme 6). 
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Scheme 6. Stereo-correlation of (+)-27a to crystallographically characterised (2S,3R)-33 via 
selective allylation, to anti-32, and Boc-deprotection. Only hydrogens on the allyl, amine and 
C2-methine groups of 33 are shown. Selected bond distances: N1-C2 1.450(6), 1.439(6); C2-
C3 1.555(6), 1.558(6); C3-C4 1.524(7), 1.543(7) Å and N1-C1-C2-C3 torsion angle: 43.4(5), 
48.2(5) o. There are two independent molecules in the unit cell of 33. 
 
A sample of 77% ee (+)-27a was allylated under non-polar mild conditions leading to the 
formation of a major allyl anti diastereomer 32 with the same optical purity, within 
experimental error as the starting material. Deprotection of 32 with trifluoroacetic acid leads 
to formation of a similar mixture of stereoisomers, of which the anti-(33) species is 
significantly the most abundant. Fortunately, slow addition of pentane to concentrated ether 
solutions of the 33 mixture leads to the formation of modest crops of yellow needles of (+)-
33, which by crystallography are the single isomer anti-(+)-(2S,3R)-33.[10] Thus (+)-27a also 
has the 2S configuration presented throughout this paper. Based on the similarity of their 
chiral (Chiralpak AD-H) HPLC enantiomer elution and the homology of their polarimetry results 
we tentatively suggest that 27a-k and 28-31 have the stereochemistry implied herein. 
 
Conclusions 
While new 1,4-addition of akyl Grignard reagents to protected quinolin-4(1H)-ones (7) proceed 
efficiently (54-99% yield) under CuBr·SMe2/PPh3 catalysis (5/10 mol-%) attempts to render 
the process asymmetric asymmetric are not successful (eemax ~11%). However, modification 
of the quinolin-4(1H)-one core by addition of a ester directing/activating group at the 3-
position allows asymmetric additions of AlR3 (R = Me, Et, nC8H17) under 
Cu(OTf)2/phosphoramidite (4/8 mol-%) catalysis. The best ligands are the dis-symmetric 
ligands introduced by Fletcher, especially (S)-LN.[19] Stereoselectivities in the range from: -45 
to +86% ee are observed, with the highest selectivities being associated with those 4(1H)-
quinolone-3-carboxylate acceptors (26) bearing small electron withdrawing substituents at the 
6-position. The sense of asymmetric induction, due to (S)-LN, could be determined by C3-
allylation and subsequent N-deprotection to afford crystals of ethyl (2S,3R)-3-allyl-2-ethyl-2,3-
dihydro-4(1H)-quinolone-3-carboxylate (2S,3R)-(33). As no general ligand providing >90% ee 
over a range of 4(1H)-quinolone-3-carboxylates was identified it is likely that individual 
substrate optimisation will be required. Rather than ad hoc screening we propose in silico 
ligand screening of a test transition state, modelled out of our own mechanistic studies,[S20] but 
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using the substrates employed here may be an attractive alternative strategy to the discovery 
of such systems.  Such investigations are our next target. 
 
Experimental Section 
Details of our general laboratory set-up and instrumentation have been already published.[21] 
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Graphical Abstract Text: 
Directing ester functions (R = CO2Et) ‘give a big hand’ to copper catalysed 1,4-additions of 
organometallics. Synthetically useful 6-halo building blocks are accessed.  
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